ResMed Ranks 365th in Trading Volume as Double-Digit Earnings Growth and 13% Dividend Hike Signal Strong Financial Health

On July 31, 2025, ResMed (RMD) closed down 1.98% with a trading volume of $0.40 billion, ranking 365th in market activity. The company released Q4 and full-year 2025 results, highlighting a 10% year-over-year revenue increase to $1.3 billion and a 19% rise in operating profit to $454.5 million. Non-GAAP metrics showed similar growth, with gross margin expanding 230 basis points to 61.4% driven by procurement and logistics efficiencies. The board also raised its quarterly dividend by 13% to $0.60 per share.

ResMed’s performance reflects strong global demand for its sleep and respiratory devices, alongside growth in its Residential Care Software division. Constant-currency revenue rose 9% across all major regions, with operating cash flow reaching $539 million in Q4. The company attributed margin expansion to cost management and favorable foreign exchange movements, though SG&A expenses increased 8% due to brand investments and marketing activities.

Strategic moves included the acquisition of VirtuOx, enhancing its at-home diagnostic capabilities, and partnerships like the Qatar Airways Lions Tour to boost brand visibility. Management emphasized continued innovation in digital health and expanding access to care. The dividend hike and $100 million in share repurchases further underscore confidence in sustained financial performance.

The backtest results indicate that a strategy of purchasing the top 500 high-volume stocks and holding them for one day generated a 166.71% return from 2022 to July 30, 2025, outperforming the benchmark by 137.53%. This highlights the role of liquidity and momentum in capturing market shifts, particularly for high-volume equities like those in the strategy’s portfolio.